Articles tagged with Glioblastomas
Research shows that brain metastases have dense concentrations of tumour infiltrating lymphocytes, providing an immunoactive environment. High expression of PDL1 is common in both glioblastoma and brain metastases, making immune checkpoint inhibitors a promising treatment option.
Researchers have made a breakthrough in brain cancer treatment by identifying a key process that can be targeted with a new drug, AZD8055, which combines with Temozolomide to extend animal life by 30%. This discovery is leading to the start of a human phase I/II clinical trial as early as Spring 2015.
Researchers have discovered a fusion protein in approximately 15% of secondary glioblastomas, offering insights into the disease's cause and potential therapeutic targets. The PTPRZ-MET fusion may be exquisitely sensitive to existing MET inhibitors, allowing for personalized oncologic care.
A CTRC doctor has been awarded a $1.6 million FDA orphan grant to study the efficacy of TH-302 in treating glioblastoma, a devastating brain tumor with a median survival time of four months. The drug, combined with Avastin, aims to slow tumor growth by creating a low-oxygen environment, sparing healthy cells from chemotherapy damage.
Researchers have identified the interleukin-13 receptor ¬ chain variant 2 (IL13R¢) as a potential target for therapy in glioblastoma multiforme (GBM). Early successes of clinical trials with targeted therapies against IL13R¢ suggest increased survival time for GBM patients.
Researchers developed a new method to detect malignant brain tumors using a handheld Raman scanner, which can identify cancerous cells with high accuracy. The technique has the potential to improve surgical outcomes and reduce tumor recurrence rates.
The Translational Genomics Research Institute has received regulatory approval for a $5 million clinical trial study on glioblastoma. The pilot trial will test new drugs to extend GBM patient survival, while also analyzing genomic data from over 536 past cases and conducting lab tests to measure cell responses.
Glioblastomas are resistant to drug therapy due to epigenetic regulation of EGFR signaling, not altered DNA sequences. This finding suggests a new approach to guiding cancer therapy by analyzing the epigenetic signature of glioblastoma cells.
Scientists have successfully tested a new treatment for aggressive brain cancer, using tiny gold nanoparticles to kill tumour cells. The treatment combines chemotherapy with radiotherapy, targeting cancer cells directly and enhancing the impact of conventional treatments.
Researchers at McGill University have identified SUMO1 as a key player in the proliferation of glioblastoma tumour cells. The study reveals that sumoylation of CDK6 protein stabilizes it, enabling cancer stem cell growth and progression. This breakthrough could lead to targeted therapies for treating brain cancer.
Researchers identified a new biomarker that predicts glioblastoma response to chemotherapy temozolomide, improving patient outcomes. The biomarker targets MGMT-regulating microRNAs, which suppress the cancer-killing effect of temozolomide.
Researchers at Henry Ford Hospital identified specific genes associated with improved survival rates among patients with glioblastoma, the most deadly form of brain tumor. The study found that patients over 70 were more likely to survive longer and that gender differences played a role in short-term survival rates.
UT Southwestern researchers found that blocking critical DNA repair mechanisms can slow down tumor growth and increase survival in glioblastoma patients. The study used a drug called NVP-BEZ235, which combined with radiation therapy significantly delayed tumor growth in mice, up to 60 days.
Researchers analyzed genomic data from The Cancer Genome Atlas and identified three molecular clusters in lower-grade brain tumors. Tumors with IDH1/IDH2 mutations and co-deletion of chromosome arms 1p and 19q have a median survival of around eight years, while those without these mutations have a median survival of only 18 months.
Researchers at Dartmouth's Geisel School of Medicine identified a potential therapeutic target for glioblastoma multiforme, a deadly form of brain cancer. The study found that STK17A protein is induced in response to DNA damage and is correlated with poorer outcomes.
Researchers at Karolinska Institutet have discovered a new mechanism to kill glioblastoma cells using Vacquinol-1, which causes uncontrolled vacuolization leading to cell explosion and necrosis. This approach may lead to new cancer treatments, potentially working for other cancer diseases.
Researchers have discovered that FDA-approved anti-psychotic drugs possess tumor-killing activity against glioblastoma. The finding is based on shRNA technology that identifies genes required for glioblastoma growth and reveals surprising links to dopamine regulation, a crucial component in treating Parkinson's disease and schizophrenia.
Researchers at Ohio State University found that inhibiting the enzyme PRMT5 can significantly improve survival in an animal model of GBM. High levels of PRMT5 are associated with aggressive growth and lower overall survival rates in brain cancer patients.
Researchers at The Wistar Institute have developed a mathematical method for classifying glioblastoma tumor cells based on gene transcript variants. This system can predict the subclasses of glioblastoma tumors with 92 percent accuracy, enabling personalized therapies.
Researchers from McGill University have identified two transcription factors controlling the expression of genes involved in GBM tumourigenesis. Impairing these proteins could significantly reduce the ability of brain tumour-initiating cells to give rise to brain tumors.
A phase 2 trial of a personalized vaccine made from patient tumor tissue showed improved survival rates compared to standard care alone. The vaccine, HSPPC-96, triggered an immune response to kill remaining tumor cells after surgery.
Researchers have found that an experimental drug targeting tumor-associated macrophages decreases glioblastoma growth and extends the survival of laboratory mice with the cancer. The treatment increases rates of programmed cell death in both the macrophages and tumor cells, leading to reduced tumor proliferation and increased survival.
Researchers discovered that glioblastoma (GBM) tumor cells hide the signaling molecule targeted by therapies, adding complexity to current models of drug resistance. The findings suggest alternative approaches that could improve outcomes for cancer patients and may have significant implications for therapeutic regimens.
Researchers at Rockefeller University Press develop a novel two-pronged approach to combat glioblastoma, a highly aggressive form of brain cancer. By combining interleukin-12 with a CTLA-4 blocking drug, the cocktail successfully eradicated tumors in mice, showing promise for future treatment.
A Northwestern University research team has developed a drug that silences a critical gene in glioblastoma, increasing survival rates by nearly 20% and reducing tumor size. The novel therapeutic uses nanotechnology to target the gene, which plays a key role in therapy resistance.
The Cancer Genome Atlas has characterized the genomic abnormalities driving glioblastoma multiforme, identifying 61 new mutated genes. Detailed clinical information is available for most cases, providing a resource for researchers to develop targeted therapies.
A clinical trial suggests that combining radiotherapy with an anti-cancer drug called APG101 blocks a cell-signalling pathway crucial for glioblastoma development. The treatment showed promising results, with patients receiving the combination therapy living longer than those treated with radiotherapy alone.
Researchers at University of Texas M.D. Anderson Cancer Center discovered that an inflammatory protein converts glioblastoma cells into their most aggressive form, leading to radiation resistance and reducing treatment effectiveness. Blocking the inflammatory response may improve outcomes for patients.
Researchers at Columbia University Irving Medical Center have identified 18 new genes responsible for glioblastoma multiforme, the most common and aggressive form of brain cancer. About 15 percent of patients may be eligible for personalized treatment with existing drugs used in other cancers.
A combination of myxoma virus and rapamycin has been shown to infect and kill both brain cancer stem cells and differentiated compartments of glioblastoma multiforme, overcoming drug resistance. This study offers promising possibilities for overcoming barriers to treating the deadliest malignant brain tumor.
A Phase III study by MD Anderson Cancer Center found no overall survival (OS) or progression-free survival (PFS) benefits for bevacizumab in newly diagnosed glioblastoma patients. However, patients on bevacizumab experienced higher rates of toxicities and symptom burden compared to placebo.
A new gene panel may help personalize therapy for newly diagnosed glioblastoma patients by identifying those most likely to benefit from bevacizumab. Researchers observed a significant association between lower mesenchymal signatures and better survival in patients taking the drug.
A clinical trial found that adding bevacizumab to standard treatment for glioblastoma did not improve overall survival or progression-free survival. However, patients in the bevacizumab arm experienced a greater decline in cognitive function and symptom burden compared to those on placebo.
Researchers found that an EGFRvIII mutation alters the splicing of genes controlling cellular metabolism, enabling rapid tumor growth. The study highlights the critical role of EGFRvIII in GBM pathogenesis and provides new targets for oncogene-specific drug development.
A modified poliovirus is infecting and killing glioblastoma brain tumor cells with encouraging results in an ongoing phase 1 study, researchers report. The virus-based therapy, known as PVSRIPO, triggers the immune system to attack infected tumor cells.
Johns Hopkins researchers have discovered that mesenchymal stem cells derived from human adipose tissue can seek out and destroy glioblastoma cancer cells in the brain. This innovative approach may provide a new tool for accessing difficult-to-reach areas of the brain where cancer cells proliferate.
Researchers describe the use of 5-aminolevulinic acid (5-ALA) fluorescence to guide resection of recurrent glioblastoma multiforme, revealing a pathway of tumor spread through brain regions inaccessible to MRI. This technique increases the success of achieving maximum resection.
Researchers at Mayo Clinic identified an association between the naturally occurring enzyme Kallikrein 6 and malignant brain tumors. Higher levels of KLK6 were associated with shorter patient survival rates, but blocking its receptors made tumor cells more susceptible to treatment.
Researchers identified ELTD1 as a promising biomarker for diagnosing gliomas, particularly high-grade glioblastoma multiforme (GBM). Studies found that ELTD1 levels were strongly associated with glioma development and prognosis.
Researchers identified a fusion between FGFR3 and TACC3 genes in human glioblastoma samples, which promoted tumor growth and progression in a mouse model. The fusion protein escaped regulation by miR-99a, indicating its potential as a prognostic marker and drug target for glioblastoma treatment.
Researchers found a small peptide that blocks antibody recognition of desmogleins, improving cell-cell adhesion and preventing skin blistering in pemphigus vulgaris. Additionally, spironolactone reduced vascular calcification in kidney disease mice, increasing their life span. A glioblastoma fusion gene promoted tumor growth and progre...
Research demonstrates that immune system's natural killer cells can kill off virus-infected tumor cells, rendering glioblastoma virotherapy less effective. The study suggests temporarily suppressing the immune system may counteract this response and enhance therapy.
A team of researchers at MD Anderson Cancer Center has identified a cancer-promoting protein's pathway into the cell nucleus and discovered how it fuels brain tumor growth. By targeting this pathway, they hope to develop new treatments for glioblastoma multiforme, the most common and lethal form of brain cancer.
A novel blood test detects and monitors brain cancer biomarkers using nanotechnology and NMR technology, offering a promising diagnostic tool for glioblastoma multiforme patients. The study demonstrates excellent detection accuracy and potential for quick results from small blood samples.
A recent Johns Hopkins study found that repeated surgeries to remove glioblastomas, the most aggressive brain tumors, can increase median survival time from 14 months to 26.6 months. This may be due to increased efficacy of radiation and chemotherapy with each successive surgery.
Researchers at the Salk Institute have discovered that glioblastoma multiforme (GBM) can originate from cortical neurons, challenging previous assumptions about its origins. This finding suggests potential new targets to treat these deadly brain tumors and may help slow progression and recurrence.
Researchers at Cedars-Sinai Medical Center found that multifocal glioblastoma patients have significantly shorter overall survival compared to those with single tumors, even when treated with the same therapies. Median overall survival for multifocal patients was six months, while single-tumor patients survived 11 months.
Researchers at UT MD Anderson Cancer Center show how PKM2 contributes to brain tumor formation and growth by influencing histone proteins. Higher levels of PKM2 expression and H3 phosphorylation are correlated with shorter survival and higher grade tumors.
A recent study published in the Proceedings of the National Academy of Sciences reveals that a modification of the tumor suppressor gene PTEN is associated with resistance to glioblastoma treatments. The research suggests that targeting PTEN modification could lead to improved treatment outcomes for patients with glioblastoma.
A study at Columbia University Irving Medical Center found that a specific gene fusion is responsible for the majority of glioblastomas, leading to dramatic slowing of tumor growth in mice. The discovery opens up new possibilities for personalized treatments using FGFR kinase inhibitors.
TGen researchers will identify genetic differences in glioblastoma patients using whole genome sequencing, with the goal of developing personalized clinical trials. The foundation's funding supports two five-year projects aimed at extending patient survival and improving treatment outcomes.
Researchers discovered that bevacizumab can lead to invasive tumors in brain cancer patients, but found a new treatment strategy by targeting both VEGF and MET. This approach may improve survival rates for drug-resistant patients, offering hope for a more effective treatment.
Researchers have discovered a new method to sub-typing GBM tumor lines using proteins expressed, which could lead to targeted drug treatments and more accurate patient prognoses. The study found that patients with the CNP subtype may live up to 10 years after diagnosis.
Researchers at UW-Madison develop combination therapy that knocks out signaling of multiple EGFR family members in brain-cancer cells, inhibiting growth and evasion of current therapies. The study's lead author reports success with lapatinib treatment, a novel drug approved by the FDA.
Researchers at Fred Hutchinson Cancer Center have successfully transplanted gene-modified blood stem cells into brain cancer patients to protect their bone marrow against chemotherapy's toxic effects. The study showed that two patients survived longer than predicted, with one remaining alive for over three years.
A new brain cancer vaccine tailored to individual patients has proven effective in a multicenter phase 2 clinical trial, extending their lives by several months. The vaccine combined with the drug Avastin showed promise in treating recurrent glioblastoma multiforme, a type of brain cancer that kills thousands of Americans every year.
Researchers have identified protein biomarkers that can help determine which GBM patients may benefit from standard treatment, enabling personalized medicine. A 'systems' approach also found networks of genes that characterize short-term survivors from long-term GBM survivors.
Glioblastoma is an incurable disease with a one-year survival rate. Researchers at the Feinstein Institute are presenting new data on potential treatments, including pharmacological inhibition of microglia and PDZ-RhoGEF.
A study published in the Journal of Experimental Medicine found that persistent protein expression may explain why brain tumors return after therapy. The research suggests blocking an active VEGF receptor could represent a new treatment option for glioblastoma cases where traditional therapies have failed.
Researchers found that Toca 511 eliminates tumors in most animals after dosing with 5-FC, providing a dramatic survival benefit. The treatment was well-tolerated and did not cause toxicity over the six-month protocol.